secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0000950170-25-065613
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics Q1 net loss $17.7M; cash $229.7M funds into 2029
--------------------------------------------------------------------

- R&D expenses $15.4M, G&A $5.0M for Q1 2025; net loss $17.7M.
- Cash and securities $229.7M as of March 31, 2025; expected runway into 2029.
- Phase 1 SAD trial ongoing for DT-216P2 (FA); MAD patient study planned mid-2025.
- Favorable Phase 1 data for DT-168 (FECD); Phase 2 biomarker trial planned H2 2025.
- Appointed Chris Storgard, M.D., as Chief Medical Officer in April 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000095017025065613/0000950170-25-065613-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000095017025065613/dsgn-20250507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-065613

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer